Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Eupraxia Pharmaceuticals Inc increased its cash reserves by 5.90%, or 1.08m. Cash Flow from Financing totalled 21.01m or -- of revenues. In addition the company used 20.68m for operations while cash used for investing totalled 73.38k.
Cash flow per share | -1.35 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.5791 |
---|---|
Tangible book value per share | 0.5791 |
More ▼
Balance sheet in USDView more
Current ratio | 2.11 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.307 |
---|---|
Total debt/total capital | 0.2545 |
More ▼